Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Sanofi-Genzyme BioVentures

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 82
Average round size
info
The average size of a deal this fund participated in
$48M
Portfolio companies 58
Rounds per year 2.73
Lead investments 10
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.29
Exits 16
Key employees 4
Stages of investment
Early Stage Venture
Late Stage Venture
Seed

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Pharmaceutical
Summary

In 1994 was created Sanofi-Genzyme BioVentures, which is appeared as VC. The fund was located in North America if to be more exact in United States. Sanofi-Genzyme BioVentures appeared to be a CVC structure as part of the corporation. The leading representative office of defined VC is situated in the Cambridge.

The average startup value when the investment from Sanofi-Genzyme BioVentures is 100-500 millions dollars. The increased amount of exits for fund were in 2017. The real fund results show that this VC is 6 percentage points less often commits exit comparing to other companies. The top activity for fund was in 2017. Despite it in 2019 the fund had an activity. The fund is constantly included in 2-6 deals per year. Deals in the range of 10 - 50 millions dollars are the general things for fund. Opposing the other organizations, this Sanofi-Genzyme BioVentures works on 3 percentage points more the average amount of lead investments.

The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the Sanofi-Genzyme BioVentures, startups are often financed by New Enterprise Associates, GE Ventures, U.S. Venture Partners (USVP). The meaningful sponsors for the fund in investment in the same round are New Enterprise Associates, Novartis Venture Fund, Atlas Venture. In the next rounds fund is usually obtained by Wellington Management, Rock Springs Capital, RA Capital Management.

For fund there is a match between the location of its establishment and the land of its numerous investments - United States. The fund has no exact preference in some founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Therapeutics, Pharmaceutical. Among the most popular portfolio startups of the fund, we may highlight Omada Health, Expansion Therapeutics, Evidation Health.

The overall number of key employees were 4.

Read more

Look at other 50 related and similar funds Collapse list
Fund NameLocation
7 Industries Netherlands, Noord-Holland, North Holland
Aries Capital Partners Salt Lake City, United States, Utah
Camel Group China, Hubei, Xiangyang
Cypherpunk Holdings Inc. Canada, Ontario, Toronto
ETH Zurich Foundation Switzerland, Zürich, Zurich
Orchid India -
Shooting Star -
Silversmith Capital Partners Boston, Massachusetts, United States
Wasatch Funds Sandy, United States, Utah

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

NextPoint Therapeutics

Biotechnology
Health Care
Life Science
Therapeutics
$42M14 Feb 2024 Cambridge, Massachusetts, United States

Sudo Biosciences

Biopharma
$30M13 Feb 2024 Menlo Park, California, United States

Sudo Biosciences

Biopharma
$116M20 Dec 2023 Menlo Park, California, United States

Eligo Bioscience

Biotechnology
Health Care
Medical
$32M05 Dec 2023 Paris, Ile-de-France, France

T-Therapeutics

Biotechnology
Health Care
Medical
$65M15 Nov 2023 Cambridge, Cambridgeshire, United Kingdom

ReCode Therapeutics

Biopharma
Biotechnology
Health Care
Pharmaceutical
Wellness
$50M19 Sep 2023 Dallas, Texas, United States

ROME Therapeutics

Biotechnology
Health Care
Pharmaceutical
$72M12 Sep 2023 Cambridge, Massachusetts, United States

Abcuro

Biotechnology
Health Care
Medical
Therapeutics
$155M17 Aug 2023 Newton, Massachusetts, United States

Tisento Therapeutics

Health Care
Medical
Therapeutics
$81M31 Jul 2023 Cambridge, Massachusetts, United States

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Sanofi-Genzyme BioVentures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 82
Average round size 48M
Rounds per year 2.73
Peak activity year 2023
Lead investments 10
Follow on index 0.29
Exits 16
Group Appearance index 0.99

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

NextPoint Therapeutics

Biotechnology
Health Care
Life Science
Therapeutics
$42M14 Feb 2024 Cambridge, Massachusetts, United States

Sudo Biosciences

Biopharma
$30M13 Feb 2024 Menlo Park, California, United States

Sudo Biosciences

Biopharma
$116M20 Dec 2023 Menlo Park, California, United States

Eligo Bioscience

Biotechnology
Health Care
Medical
$32M05 Dec 2023 Paris, Ile-de-France, France

T-Therapeutics

Biotechnology
Health Care
Medical
$65M15 Nov 2023 Cambridge, Cambridgeshire, United Kingdom

ReCode Therapeutics

Biopharma
Biotechnology
Health Care
Pharmaceutical
Wellness
$50M19 Sep 2023 Dallas, Texas, United States

ROME Therapeutics

Biotechnology
Health Care
Pharmaceutical
$72M12 Sep 2023 Cambridge, Massachusetts, United States

Abcuro

Biotechnology
Health Care
Medical
Therapeutics
$155M17 Aug 2023 Newton, Massachusetts, United States

Tisento Therapeutics

Health Care
Medical
Therapeutics
$81M31 Jul 2023 Cambridge, Massachusetts, United States
Crunchbase icon

Content report

The following text will be sent to our editors: